Abstract:

The aim of this study is to evaluate the perspectives of infertile patients on the Coronavirus disease-2019 (COVID-19) vaccine and to measure the effect of the COVID-19 vaccine administered on women's ovarian reserve tests and in vitro fertilization (IVF) treatment outcomes. This prospectively planned study was conducted in Hüma Gynecology and Obstetrics Hospital, IVF Unit. The study included 187 patients who applied due to infertility between April 2022 and June 2022. The patients were divided into 2 groups according to whether they had the COVID-19 vaccine or not. Follicle Stimulating Hormone (FSH), Estradiol (E2), Anti Müllerian Hormone (AMH) values, and total antral follicle counts (AFS) of 94 patients in the 1st group who accepted to be vaccinated were measured. The same parameters of 93 patients who refused to be vaccinated were also examined. The results of ovarian reserve tests and IVF treatment were compared between these two groups with and without vaccination. When the ovarian reserve tests of the vaccinated patients were evaluated before and after vaccination, no statistically significant difference was found in terms of FSH, AMH, E2, and AFS. No statistically significant difference was observed in the number of oocytes collected, the number of M2 oocytes, fertilization, implantation, and clinical pregnancy rates between the group that received the vaccine and the group that did not receive the vaccine during the IVF treatment process (p>0.05). It has been shown in our study that the COVID-19 vaccine does not reduce ovarian reserve while protecting people from infection. It has also been proven in this study that vaccination before IVF treatment in infertile patients does not adversely affect the treatment process and results.